Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMSCs in Mandibular Fractures
NCT02755922Phase 3Completed
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Apr 2010
- Primary completion
- Sep 2010
- Modality
- Stem Cell Therapies
01
Overview
Phase 3, randomised, single-blind trial of autologous mesenchymal stem cells in mandibular fracture (2 arms), sponsored by Instituto Mexicano del Seguro Social. Primary endpoint: Change of bone quality at 12 weeks. Started Apr 2010; status: completed.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
mandibular fracture
Beyond the preview
Go deeper on NCT02755922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02755922.